Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTM-N2D in Relapsed or Refractory Solid Tumors
NCT04107142Phase 1Unknown
- Sponsor
- CytoMed Therapeutics
- Start
- Dec 2019
- Primary completion
- Sep 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of allogeneic NKG2DL-targeting CAR-grafted gamma delta T cells in colorectal cancer (CRC), triple-negative breast cancer (TNBC), sarcoma and 3 more, sponsored by CytoMed Therapeutics. Primary endpoint: Dose Limiting Toxicity at 6 months. Status: unknown.
02
Drugs
allogeneic NKG2DL-targeting CAR-grafted gamma delta T cells
03
Conditions
colorectal cancer (CRC)triple-negative breast cancer (TNBC)sarcomanasopharyngeal carcinoma (NPC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04107142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04107142.